What is dementia? Dementia is an umbrella term for several diseases that affect memory, thinking, and the ability to perform daily activities rather than one…
Номе
Sacubitril/valsartan shows benefit in heart failure with ejection fraction above 40%
Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction…
Combining generative AI and quantum computing to accelerate drug discovery
The study, published May 13 in the American Chemical Society's Journal of Chemical InformInsilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery…
Semaglutide shown to be effective for weight loss in multicenter, one-year real-world study
Source: Read Full Article
New study examines treatment outcomes of pregnant women with cannabis use disorder
Source: Read Full Article
An AI chatbot may be your next therapist. Will it actually help your mental health?
In the past few years, 10,000 to 20,000 apps have stampeded into the mental health space, offering to “disrupt” traditional therapy. With the frenzy around…
Glioblastoma: New combination therapy may boost survival
Researchers investigated a novel combination treatment involving an oncolytic virus and immunotherapy for recurrent glioblastoma. The treatment increased survival rates from 6–8 months to 12.5…
Are US prescription drug prices 10 times those of other nations? Only sometimes
Sen. Bernie Sanders (I-Vt.), whether in Congress or as a presidential candidate, has always taken strong positions against the high cost of prescription drugs. Since…
Variation seen in cancer-specific mortality rates across countries
Recent mortality rates decreased for major cancers in most of 47 studied countries, apart from lung cancer in women and liver cancer in men, according…
U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohns Disease in Adults
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib)…